Gene Therapy Stocks Continue To Underperform. Are They Worth A Look?
- Wednesday, September 30, 2020, 7:17
- Market
- Add a comment
Gene therapy – which aims to treat diseases by essentially inserting a gene into a patient’s cells rather than via drugs or surgery – was a hot trend in the biotech space, but investor interest in the sector appears to have died down considerably, on account of high R&D spending and delays…
About the Author
admin123 has written 23400 stories on this site.
